Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate

被引：0
|
作者：
R. A. Wermers
C. P. Recknor
F. Cosman
L. Xie
E. V. Glass
J. H. Krege
机构：
[1] Mayo Clinic,Division of Endocrinology and Metabolism
[2] United Osteoporosis Centers,Clinical Research Center
[3] Helen Hayes Hospital,Eli Lilly and Company
[4] Lilly Corporate Center,undefined
来源：
Osteoporosis International | 2008年 / 19卷
关键词：
Alendronate; Hypercalcemia; Postmenopausal osteoporosis; Raloxifene; Serum calcium; Teriparatide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1055 / 1065
页数：10
相关论文
共 50 条
  • [21] Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women
    Ringe, J. D.
    Christodoulakos, G. E.
    Mellstroem, D.
    Petto, H.
    Nickelsen, T.
    Marin, F.
    Pavo, I.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (11) : 2677 - 2687
  • [22] EFFECTS OF ODANACATIB ON BMD AND SAFETY IN POSTMENOPAUSAL WOMEN PREVIOUSLY TREATED WITH ALENDRONATE
    De Villiers, Tobie
    Bonnick, Sydney
    Odio, Alberto
    Palacios, Santiago
    Chapurlat, Roland
    Scott, Boyd
    De Tilleghem, Celine Le Bailly
    Leung, Albert
    Gurner, Deborah
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S36 - S37
  • [23] DENOSUMAB COMPARED WITH ALENDRONATE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN PREVIOUSLY TREATED WITH ALENDRONATE
    Bernad, M.
    Garces, M.
    Martin Mola, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 768 - 768
  • [24] Effects of raloxifene and alendronate on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis
    Johnell, O
    Lu, Y
    Seeman, E
    Reginster, J
    Scheele, W
    OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S184 - S184
  • [25] A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis
    Stevenson, M
    Jones, ML
    De Nigris, E
    Brewer, N
    Davis, S
    Oakley, J
    HEALTH TECHNOLOGY ASSESSMENT, 2005, 9 (22) : 1 - +
  • [26] Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
    Mei Li
    Zhenlin Zhang
    Qingyun Xue
    Qifu Li
    Xiaolan Jin
    Jin Dong
    Qun Cheng
    Li You
    Hua Lin
    Hai Tang
    Lin Shen
    Xin Gao
    Ji Hu
    Aijun Chao
    Pengqiu Li
    Rui Shi
    Shuhui Zheng
    Ying Zhang
    Xiaojiang Xiong
    Wei Yu
    Weibo Xia
    Archives of Osteoporosis, 2022, 17
  • [27] Comparison of raloxifene and alendronate on markers of cardiovascular health in postmenopausal women with osteoporosis.
    Adachi, JD
    Reginster, J
    Qu, Y
    Siddhanti, S
    Keech, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S379 - S379
  • [28] Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
    Li, Mei
    Zhang, Zhenlin
    Xue, Qingyun
    Li, Qifu
    Jin, Xiaolan
    Dong, Jin
    Cheng, Qun
    You, Li
    Lin, Hua
    Tang, Hai
    Shen, Lin
    Gao, Xin
    Hu, Ji
    Chao, Aijun
    Li, Pengqiu
    Shi, Rui
    Zheng, Shuhui
    Zhang, Ying
    Xiong, Xiaojiang
    Yu, Wei
    Xia, Weibo
    ARCHIVES OF OSTEOPOROSIS, 2022, 17 (01)
  • [29] Histomorphometric Changes by Teriparatide in Alendronate Pre-treated Women with Osteoporosis
    Stepan, J. J.
    Dobnig, H.
    Burr, D. B.
    Li, J.
    Ma, Y. L.
    Sipos, A.
    Petto, H.
    Pavo, I.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S6 - S7
  • [30] EFFECTS OF TERIPARATIDE ON VERTEBRAL BODY BIOMECHANICS IN POSTMENOPAUSAL WOMEN TREATED PREVIOUSLY WITH RISEDRONATE OR ALENDRONATE: A QCT-BASED FINITE ELEMENT STUDY
    Zysset, P.
    Quek, E.
    Borah, B.
    Gross, G.
    Stewart, J.
    Lang, T.
    Chevalier, Y.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 154 - 154
12345